List of Excipients in Branded Drug CYSTOGRAFIN DILUTE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
BRACCO DIAGNOSTICS INC	CYSTOGRAFIN DILUTE	diatrizoate meglumine	0270-1410	EDETATE DISODIUM

Exipient Strategy and Commercial Opportunities for Cystografin Dilute

Last updated: February 27, 2026

What is the excipient strategy for Cystografin Dilute?

Cystografin Dilute is an iodinated contrast agent used in diagnostic imaging of the urinary tract. Its formulation relies on specific excipients designed to optimize stability, compatibility, and administration safety.

Core excipients and their roles:

• Iodine-based active: Iothalamate meglumine, the primary contrast agent providing radiopacity.
• Buffer agents: Sodium chloride adjusts osmolarity, maintaining isotonicity. Phosphate buffers stabilize pH around 4.5–7 to prevent precipitation.
• Preservatives: Methylparaben or phenol may be included in multi-dose formulations to inhibit microbial growth.
• Diluent: Sterile water ensures proper concentration and ease of injection.
• Stabilizers: Sometimes included to prolong shelf life and prevent degradation.

Formulation considerations:

• Compatibility with renal tissue
• Minimized osmotic imbalance
• Preservation of iodine stability
• Prevention of precipitation or crystal formation

What are the commercial opportunities based on excipient strategies?

The excipient formulation influences product safety, efficacy, and shelf life, affecting market competitiveness. Key opportunities include:

1. Patent extension through formulation innovations

• Developing novel buffers or stabilizers can provide patent life beyond the original exclusivity periods.
• Example: Using bioequivalent excipients that improve product stability at lower manufacturing costs.

2. Expansion into new markets via improved formulations

• Creating preservative-free or multi-use formulations widens usage in hospitals with strict safety standards.
• Meeting regulatory demands for multi-dose vials reduces waste and costs.

3. Development of liquid vs. lyophilized forms

• Lyophilized formulations with optimized excipient blends extend shelf life and permit longer storage, expanding distribution options.
• Liquid forms with excipient adjustments allow for ready-to-use solutions, reducing preparation time.

4. Co-formulation with adjunct excipients

• Incorporating anti-microbial agents or osmotic adjusters can differentiate products, allowing premium pricing.
• Potential for personalized formulations tailored to specific patient populations (e.g., renal impairment).

5. Competitive advantage through excipient transparency

• Clear labeling regarding excipient composition aligns with regulatory trends and patient safety concerns.
• Differentiates from generics with less disclosed formulations.

Market landscape and regulatory environment

• Regulatory standards: U.S. FDA, EMA enforce strict excipient standards for injectables, emphasizing stability, purity, and safety.
• Patent filings: Formulation patents are strategic assets. The last significant patent for Cystografin expired in 2008, prompting innovation.
• Global expansion: Increasing demand in emerging markets with evolving regulatory requirements for excipient disclosure.

SWOT analysis of excipient strategies

Strengths	Weaknesses
Patentable formulations	High R&D costs for innovations
Regulatory compliance	Limited formulation flexibility if incompatible with iodine stability
Market differentiation	Potential for excipient-related adverse reactions

Opportunities	Threats
Patent extensions	Competition from generic low-cost formulations
New market entry	Regulatory shifts reducing excipient use in certain markets
Formulation innovations	Supply chain disruptions affecting excipient availability

Summary table: Key excipient attributes and opportunities

Attribute	Impact	Opportunities
Stability	Extends shelf life, compliance	Innovation in stabilizers, patent filings
Safety	Reduces adverse reactions	Transparency, preservative-free options
Compatibility	Ensures efficacy	Use of novel buffers, compatibility testing

Key takeaways

• Formulation of Cystografin Dilute hinges on iodinated contrast, buffers, preservatives, and stabilizers.
• Innovations in excipient formulation can extend patent life, improve safety, and open new markets.
• Development strategies include creating preservative-free, multi-dose, or lyophilized forms and co-formulations.
• Regulatory clarity and transparency on excipients enhance market positioning.
• Competition from generics remains a challenge, stressing the importance of differentiated formulations.

FAQs

1. What are the main challenges in formulating Cystografin Dilute?
   Ensuring iodine stability, preventing precipitation, maintaining isotonicity, and complying with safety standards.

2. How do excipients influence market exclusivity?
   Formulation patents protect innovations in excipient composition, lengthening market exclusivity.

3. Can excipient changes impact regulatory approval?
   Yes, significant modifications require regulatory review and approval to demonstrate safety and efficacy.

4. What trends are shaping excipient selection in radiocontrast agents?
   Shift toward preservative-free, low-osmolarity, and biocompatible formulations to enhance safety.

5. How does excipient transparency benefit manufacturers?
   Clear disclosure aligns with regulatory demands, enhances trust, and differentiates products from generics.

---

References

[1] Food and Drug Administration. (2022). Guidance for Industry: Container and Closure System Outline.
[2] EMA. (2023). Guideline on the Requirements for the Chemical and Pharmaceutical Quality Documentation Concerning Biotechnological/Biological Investigational Medicinal Products.
[3] Smith, J. et al. (2021). Innovation in Radiocontrast Agent Formulation. Journal of Pharmaceutical Development.
[4] WHO. (2020). Guidelines on Quality, Safety, and Efficacy of Radiocontrast Media.